United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt) -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; hypromellose; macrogol 8000; microcrystalline cellulose; titanium dioxide; poloxamer; hyprolose; povidone; macrogol 400; iron oxide red - prophylaxis of plasmodium falciparum malaria in adults and children 11kg and over; treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atovaquone, quantity: 150 mg/ml - oral liquid, suspension - excipient ingredients: poloxamer; saccharin sodium; benzyl alcohol; purified water; xanthan gum; flavour - wellvone suspension is indicated for: acute treatment of mild to moderate pneumocystis carinii pneumonia (pcp) (difference of alveolar and arterial oxygen tensions [(a-a)do2]<=45mmhg(6kpa) and oxygen tension in arterial blood (pa02)>=60mmhg(8kpa) breathing room air) in adult patients with aids who are intolerant of trimethoprim/sulphamethoxazole therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - atovaquone, quantity: 250 mg; proguanil hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: poloxamer; hyprolose; hypromellose; macrogol 400; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; macrogol 8000; iron oxide red; povidone - malarone is indicated for the treatment of plasmodium falciparum malaria in adults and children aged 3 years or older. indications as at 1 november 2001: "prophylaxis of plasmodium falciparum malaria in individuals weighing >40kg". this approval is based on the evaluation of the information and data provided with the original letter of application and with any subsequent correspondence and submissions relating to the application. indications as at 13 january 2003: prophylaxis of plasmodium falciparum malaria in adults and children 11kg and over; treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - atovaquone - oral suspension - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - atovaquone - oral suspension - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - atovaquone - oral suspension - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - atovaquone - oral suspension - 150mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; poloxamer; magnesium stearate; hyprolose; purified water; povidone; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: povidone; poloxamer; colloidal anhydrous silica; purified water; magnesium stearate; hyprolose; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.